✦ LIBER ✦

Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients

✍ Scribed by Skřičková, Jana; Kadlec, Bohdan; Venclíček, Ondřej; Janásková, Tereza; Bartoš, Jiří; Chalupa, Jiří; Kolek, Vítězslav; Grygárková, Ivona; Čoupková, Helena; Reiterer, Pavel

Book ID: 119320889
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 57 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.073

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1 study of linifanib in combinat

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Horinouchi, Hidehito; Yamamoto, Noboru; Nokihara, Hiroshi; Horai, Takeshi; Nishi 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 417 KB

A phase II study of carboplatin and pacl

A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)

✍ Giorgio, Carmelo Giannitto; Pappalardo, Alessandro; Russo, Antonio; Giuffrida, D 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 95 KB

A phase II study of docetaxel (D) and ge

A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)

✍ Agelaki, S.; Papadakis, E.; Tsiafaki, X.; Rapti, A.; Toubis, M.; Bania, E.; Kalb 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 158 KB

PD-147 A phase I study of a second gener

PD-147 A phase I study of a second generation antisenseoligonucleotide to clusterin (OGX-011) in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Preliminary results

✍ Laskin, J.; Chi, K.; Melosky, B.; Sill, K.; Hao, D.; Canil, C.; Gleave, M.; Murr 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 129 KB

P-976 EGFR mutation analysis in a random

P-976 EGFR mutation analysis in a randomized phase II study of cetuximab (Erbitux™) in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts)

✍ Szczesna, A.; Taron, M.; Robinet, G.; Ramlau, R.; Pfeifer, W.; Kolb, R.; Consten 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 117 KB